Peptide Immunotherapy for MS: Where the Research Stands
Autoimmune Peptide Therapies
78% reduction
In brain lesions seen in a Phase 2a trial of ATX-MS-1467, a four-peptide mixture derived from myelin basic protein, administered to relapsing MS patients over 16 weeks.
Chataway et al., Neurology, 2018
Chataway et al., Neurology, 2018
View as imageMultiple sclerosis strips myelin from nerve fibers because the immune system mistakes its own proteins for threats. Every approved MS drug works by suppressing or redirecting the immune system broadly, which lowers infection defense alongside the autoimmune attack. Peptide immunotherapy takes a different approach: feed the immune system the exact myelin fragments it is reacting against, under conditions that teach tolerance instead of aggression. The concept has worked repeatedly in animal models of MS. Translating it into humans has proven far harder. This article tracks what has been tried, what failed, what showed early promise, and where the field is heading. For broader context on how peptides are being used across autoimmune diseases, see Peptide Therapies for Autoimmune Disease: Teaching Tolerance.
Key Takeaways
- Altered peptide ligands (APLs) based on myelin basic protein (MBP 83-99) reached Phase II trials in 2000 but were halted after some patients developed disease flares and hypersensitivity reactions[2][3]
- ATX-MS-1467, a four-peptide MBP mixture, reduced contrast-enhancing brain lesions by 78% in a Phase 2a open-label trial of 93 relapsing MS patients
- The ETIMS trial demonstrated that autologous cells coupled with seven myelin peptides were safe in 9 MS patients, with higher doses reducing antigen-specific T cell responses[4]
- GLP-1 receptor agonists like NLY01 and liraglutide reduced demyelination and neuroinflammation in mouse EAE models through mechanisms distinct from myelin tolerance[6][7][9]
- Nanoparticle platforms delivering myelin peptides with tolerogenic signals to liver antigen-presenting cells induced durable CD4+ T cell tolerance in 2025 preclinical work[10]
- Glatiramer acetate remains the only FDA-approved peptide-based MS therapy, working through immune deviation rather than antigen-specific tolerance
Why MS Is a Hard Target for Peptide Tolerance
Most autoimmune diseases attack a limited set of self-proteins. MS attacks several. The immune system in MS patients recognizes fragments of myelin basic protein (MBP), proteolipid protein (PLP), and myelin oligodendrocyte glycoprotein (MOG), among others.[5] Worse, the target list expands over time through a process called epitope spreading: as myelin breaks down, newly exposed protein fragments become targets for additional immune attacks.
This means a peptide vaccine targeting one myelin fragment might calm one arm of the autoimmune response while leaving others intact. The multi-epitope challenge has derailed several clinical programs and shaped every subsequent approach to peptide immunotherapy in MS.
The animal model used to test these therapies, experimental autoimmune encephalomyelitis (EAE), is induced by immunizing mice with a single known myelin peptide. Tolerance to that one peptide often cures the mice.[1] Human MS, with its shifting constellation of targets, is a fundamentally different challenge.
Altered Peptide Ligands: The First Clinical Attempts
The earliest peptide immunotherapy strategy for MS involved altered peptide ligands (APLs), synthetic versions of myelin peptides with one or two amino acid substitutions. The idea: these modified peptides bind the same T cell receptors as real myelin fragments but deliver a different signal, shifting the immune response from inflammatory (Th1) to anti-inflammatory (Th2). In mice, an APL based on the MBP 83-99 epitope prevented EAE by inducing immune deviation toward Th2 cytokines.[1]
Two Phase II trials tested APLs in MS patients in 2000, and both ran into trouble. Bielekova and colleagues found that some patients receiving high-dose APL injections developed exacerbations of their disease, with increased MBP-reactive T cells and new inflammatory brain lesions on MRI. The trial was stopped early.[2] A parallel trial by the Altered Peptide Ligand in Relapsing MS Study Group (Kappos et al.) found that while lower doses induced the desired Th2 shift, three patients experienced immediate-type hypersensitivity reactions at higher doses, also forcing early termination.[3]
These trials exposed a critical risk: the line between tolerizing the immune system and activating it further is thin. A peptide designed to calm can instead inflame, particularly when the immune system is already primed against the target antigen. Both trials targeted a single MBP epitope, leaving the broader autoimmune response unaddressed. For a deeper look at how APLs work across autoimmune conditions, see Altered Peptide Ligands: Tricking the Immune System into Tolerance.
ATX-MS-1467: A Multi-Peptide Approach
Learning from the single-epitope failures, Apitope Technology developed ATX-MS-1467, a mixture of four short peptides derived from MBP (residues 30-44, 83-99, 131-145, and 140-154). These are "apitopes" (antigen processing-independent epitopes), peptides short enough that they bind directly to MHC class II molecules on the cell surface without needing to be processed inside antigen-presenting cells. This bypasses the inflammatory machinery inside the cell.
A first-in-human Phase I study in six patients with secondary progressive MS tested escalating intradermal doses from 25 to 800 mcg. The treatment reduced T cell responses to MBP and was well tolerated. A subsequent Phase I study in 43 adults with relapsing-remitting MS (RRMS) found that intradermal (but not subcutaneous) administration reduced the number and volume of active inflammatory lesions over 16 weeks of treatment.
The Phase 2a trial enrolled 93 patients with relapsing MS in a multicenter, open-label, baseline-controlled design. After 16 weeks of intradermal ATX-MS-1467 injections, contrast-enhancing brain lesions dropped by 78%, disability scores improved on the MS Functional Composite, and no serious adverse events occurred. The open-label design and lack of a placebo arm limit what can be concluded, but the safety data and MRI signal were strong enough to advance the program.
Myelin Peptide-Coupled Cells: The ETIMS Approach
Rather than injecting free peptides, the ETIMS (Establish Tolerance in MS) trial used a different delivery method. Researchers drew patients' own blood cells (peripheral blood mononuclear cells), chemically coupled seven different myelin peptides to their surface (MOG 1-20, MOG 35-55, MBP 13-32, MBP 83-99, MBP 111-129, MBP 146-170, and PLP 139-154), and infused them back intravenously.[4]
The rationale: when cells carrying antigen on their surface undergo apoptosis (programmed cell death), the immune system interprets this as a signal to tolerate that antigen rather than attack it. By coupling multiple myelin peptides to the cells, the approach addresses multiple autoantigens simultaneously, avoiding the single-epitope limitation that undermined the APL trials.
The Phase 1 dose-escalation trial in 9 MS patients (7 RRMS, 2 secondary progressive) showed the approach was feasible and safe. The four patients receiving the highest doses (above 1 billion peptide-coupled cells) showed decreased antigen-specific T cell responses three months after treatment.[4] The multi-peptide strategy appeared to engage tolerance across several myelin targets at once.
The manufacturing complexity is the tradeoff. Each dose requires drawing, processing, and returning a patient's own cells, a personalized procedure that is expensive and difficult to scale. This has driven research toward off-the-shelf alternatives, including nanoparticles that mimic the same tolerogenic cell death signal.
Glatiramer Acetate: The Peptide-Based Drug That Made It
Glatiramer acetate (Copaxone) is the only FDA-approved peptide-based therapy for MS. It is not a precise peptide immunotherapy. It is a random mixture of synthetic polypeptides composed of four amino acids (glutamic acid, lysine, alanine, and tyrosine) in a fixed ratio, originally designed to mimic myelin basic protein.
Its mechanism is broad rather than antigen-specific. Glatiramer acetate competes with myelin fragments for binding to MHC class II molecules on antigen-presenting cells, reducing the presentation of true myelin antigens to T cells. It shifts the T cell population from inflammatory Th1 cells to regulatory Th2 cells that cross the blood-brain barrier and secrete anti-inflammatory cytokines including IL-10 and TGF-beta, along with brain-derived neurotrophic factor. It also modulates dendritic cells, monocytes, and CD8+ T cells.
Glatiramer acetate reduces relapse rates by roughly 30% in RRMS. This is modest compared to newer monoclonal antibody therapies, but its safety profile over 25+ years of clinical use is well established. It demonstrates that a peptide-based approach can modify MS, even if the mechanism is immune deviation rather than true antigen-specific tolerance. What the field wants is a therapy that achieves what glatiramer does, but more precisely: shutting down only the autoimmune component while leaving the rest of the immune system intact.
Tolerogenic Dendritic Cells Loaded with Myelin Peptides
Dendritic cells are the immune system's instructors. They present antigens to T cells and determine whether the response will be inflammatory or tolerogenic. Researchers have exploited this by generating tolerogenic dendritic cells (tolDCs) in the lab, loading them with myelin peptides, and injecting them back into MS patients.
A Phase 1b trial tested autologous tolDCs loaded with seven myelin-derived peptides (the same set used in the ETIMS trial) in MS and neuromyelitis optica patients. The treatment was safe and feasible. Individual regulatory T cells secreting IL-10, a key tolerogenic cytokine, were detected after treatment, indicating that the tolerogenic signal reached the right immune cells.
This approach shares the manufacturing burden of the ETIMS method: each patient needs their own dendritic cells generated from a blood draw, matured under specific conditions, loaded with peptides, and returned. The biological complexity makes standardization and scaling difficult.
GLP-1 Receptor Agonists: An Unexpected MS Connection
While the approaches above target myelin-specific immune responses, GLP-1 receptor agonists appear to protect against MS-like disease through anti-inflammatory and neuroprotective mechanisms that have nothing to do with myelin tolerance.
Lee and colleagues (2018) showed that activating the GLP-1 receptor in mice with EAE reduced neuroinflammation, decreased demyelination, and promoted neuroprotection. The drug reduced infiltration of inflammatory cells into the central nervous system and lowered levels of pro-inflammatory cytokines.[6]
NLY01, a long-acting GLP-1 receptor agonist, reduced EAE severity in mice by suppressing microglial activation and astrocyte conversion to a neurotoxic phenotype.[7] Song and colleagues (2025) demonstrated that liraglutide attenuated EAE severity by modulating splenic T helper cell subsets, shifting the balance away from inflammatory Th1 and Th17 cells and toward regulatory cells.[9]
These are animal studies, and GLP-1 agonists are not being tested in MS clinical trials. But the data is consistent across multiple independent labs, and millions of people are already taking GLP-1 drugs for diabetes and obesity. Epidemiological studies examining MS incidence or progression in GLP-1 users could provide signal without requiring new trials.
Nanoparticle Platforms: Tolerance Without Cell Manufacturing
The biggest practical barrier to peptide-coupled cells and tolerogenic DCs is manufacturing: each dose is personalized and perishable. Nanoparticle platforms aim to deliver the same tolerogenic signal using off-the-shelf particles that can be manufactured at scale.
Wang and colleagues (2025) developed a nanoparticle platform that preferentially targets liver sinusoidal endothelial cells (LSECs), which naturally promote immune tolerance. The particles delivered myelin peptide antigens to LSECs, which then presented them to CD4+ T cells in a tolerogenic context, inducing durable tolerance in EAE and other CD4+ T cell-mediated disease models.[10]
A separate approach from Urbonaviciute and colleagues (2023) used soluble peptide-based tolerizing vaccines to induce antigen-specific tolerance in autoimmune arthritis models.[8] The principle, delivering peptide antigens with tolerogenic adjuvants, applies directly to MS if the right myelin peptides and delivery signals are combined. Acetalated dextran nanoparticles co-loaded with myelin peptide and rapamycin (an immunosuppressant) have also shown efficacy in EAE without broad immune suppression.
Nanoparticle delivery solves the manufacturing problem but introduces its own challenges: ensuring the particles reach the right antigen-presenting cells, achieving consistent tolerogenic signaling across patients, and demonstrating that tolerance is durable without repeated dosing.
Epitope Mapping: Knowing What to Target
Effective peptide immunotherapy requires knowing which myelin fragments the immune system is attacking in each patient. Pacini and colleagues (2016) used microwave-assisted peptide synthesis and ELISA screening to map anti-MOG antibody epitopes in a mouse model of MS, identifying the specific peptide regions recognized by the autoimmune response.[5]
PACAP (pituitary adenylyl cyclase-activating polypeptide) takes a different angle on immune regulation. Tan and colleagues (2009) demonstrated that PACAP is an intrinsic regulator of regulatory T cell abundance, and PACAP-deficient mice developed more severe EAE with reduced Treg populations.[11] Endogenous neuropeptides like PACAP and VIP appear to set the baseline level of immune tolerance in the nervous system.
Personalized epitope mapping could theoretically allow each patient's peptide immunotherapy to be tailored to their specific autoimmune targets. The technology exists. The clinical infrastructure to make this practical does not, at least not yet. Similar challenges face peptide approaches to type 1 diabetes, where the target autoantigen is better defined but tolerance induction still proves difficult.
What Has Failed and Why
The pattern across MS peptide immunotherapy is consistent: preclinical success followed by clinical disappointment or limited efficacy.
Single-epitope targeting fails because MS involves multiple autoantigens that change over time. The APL trials targeting MBP 83-99 alone did not suppress the broader autoimmune response.[2][3]
Dose finding is treacherous. Too little peptide does nothing. Too much activates the very immune responses you are trying to suppress. The APL trials found this boundary the hard way.
Timing matters. Most trials enroll patients with established MS. By that point, epitope spreading has diversified the autoimmune attack. Earlier intervention, before the target list expands, might produce different results.
EAE is not MS. The animal model responds to single-peptide tolerance because the disease is induced with a single peptide. Human MS involves spontaneous autoimmunity against a shifting set of targets in a genetically diverse population.
Where the Field Is Heading
The next generation of MS peptide immunotherapy converges on three principles: target multiple epitopes simultaneously, deliver peptides through tolerogenic pathways (liver targeting, apoptotic cell mimicry, tolerogenic adjuvants), and intervene early before extensive epitope spreading.
Nanoparticle platforms that deliver multi-peptide payloads to tolerogenic antigen-presenting cells in the liver or spleen represent the most scalable path forward.[10] The ETIMS approach validated multi-peptide tolerization in humans but needs a manufacturing solution.[4] ATX-MS-1467's Phase 2a MRI data is encouraging but needs placebo-controlled confirmation. GLP-1 agonists offer a complementary anti-inflammatory mechanism that could work alongside antigen-specific approaches.
The field also intersects with broader autoimmune peptide research, including tolerogenic peptides and peptide research in lupus, where similar tolerance-induction strategies are being explored for different autoantigens.
No peptide immunotherapy has yet matched glatiramer acetate's track record in MS. But glatiramer works through broad immune modulation, not precision tolerance. The promise of peptide immunotherapy is specificity: stopping the autoimmune attack on myelin without compromising the immune system's ability to fight infections and cancer. That promise remains unfulfilled but technically closer than at any point in the field's history.
The Bottom Line
Peptide immunotherapy for multiple sclerosis has progressed from single-epitope altered peptide ligands that caused disease flares in the early 2000s to multi-peptide approaches (ATX-MS-1467, ETIMS) that showed safety and early efficacy signals. Nanoparticle platforms and GLP-1 agonists represent newer research directions. Glatiramer acetate remains the only approved peptide-based MS drug, but it works through broad immune modulation rather than antigen-specific tolerance. The central challenge is unchanged: inducing durable tolerance to multiple, shifting myelin targets without triggering the immune activation that peptide delivery can provoke.